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Background and aims: HIV-positive drug users’ poor adherence to 
antiretroviral regimens can pose a significant and negative impact on individual and 
global health. This review aims to identify knowledge gaps and inconsistencies within 
the current evidence base and to measure HIV-positive drug users’ adherence rates 
and the factors that influence their adherence.   
Methods: A search of quantitative and qualitative studies in relation to HIV-positive 
drug users’ adherence to antiretroviral treatment was performed using five 
databases: Applied Social Sciences Index and Abstract (ASSIA), Cumulative Index 
to Nursing and Allied Health Literature (CINAHL), Medline, Embase and PsycINFO 
(Ovid interface). Relevant studies were retrieved based on the inclusion and 
exclusion criteria stated in the review. Findings were compared, contrasted, and 
synthesised to provide a coherent account of HIV-positive drug users’ adherence 
rates and the factors that influence their adherence.   
Results: The proportion of HIV-positive drug users who achieved ≥ 95% 
adherence across the studies varied widely, from 19.3%-83.9%. Adherence rates 
changed over the course of HIV treatment. The factors that influenced adherence 
were reported as follows: stigmatisation, motivation, active drug use, accessibility 
and conditionality of HIV and addiction care, side effects and complexity of treatment 
regimens, forgetfulness and non-incorporation of dosing times into daily schedules.  
Conclusions:  HIV-positive drug users’ medication-taking is a dynamic social 
process that requires health professionals to assess adherence to HIV treatment on 
a regular basis.  
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The literature on Human Immunodeficiency Virus (HIV)-positive individuals’ 
adherence to Highly Active Antiretroviral Therapy (HAART) reveals the importance of 
strict adherence for maximum therapeutic impact. A cut-off of 95% or better 
adherence has been studied as the appropriate threshold for clinical efficacy, and 
this finding is consistent throughout empirical research and government publications 
[1-5]. Individuals with poor adherence to long-term HAART compromise the 
effectiveness of the treatment and pose a threat to the public, including incomplete 
viral suppression, increased HIV transmission, development of drug resistance, and 
limitation of treatment options [2, 6-7].  
Despite the importance of adherence to HAART, there is a growing body of literature 
that recognises that among the general HIV population, HIV-positive drug users have 
lower adherence rates compared to other HIV groups [3, 8-15]. In light of this 
evidence in the existing literature, it is becoming extremely difficult to ignore the 
existence of the importance of understanding HIV-positive drug users’ adherence 
behaviour.  
Adherence refers to “the extent to which patients’ behaviours matches agreed 
recommendations from the prescriber [2: p.12]” This term is adopted more by many 
as an alternative to compliance, because adherence involves ‘patient’s agreement’ 
to doctor’s recommendations [2]. To date, a systematic understanding of HIV-
positive drug users’ adherence to HAART is still lacking. Only two systematic 
reviews have been done to investigate the rates of adherence to HAART among 
HIV-positive drug users and its influencing factors [10,16]. 
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Feelemyer et al. [16] conducted a systematic review of 15 empirical studies aiming to 
examine the levels of adherence to HAART among people with active injection drug 
use or with a history of injection drug use in transitional/low/middle income countries. 
The results of this review showed that the adherence levels ranged from 33%-97%, 
and the overall mean weighted adherence among all studies was 71.9%. However, 
several issues were identified in this review article. Firstly, most of the included 
studies did not focus on HIV-positive drug users but the general HIV population. 
Secondly, twelve out of fifteen studies did not aim to measure adherence rates, and 
some of those did not have such data. Of the 15 studies, it was found that only one 
study appeared to be related to HIV-positive drug users’ adherence to HAART. 
Therefore, the level of adherence to HAART among drug users remains unclear in 
the current evidence base.  
Malta and her associates’ systematic review of 41 quantitative studies aimed to 
assess the adherence to HAART among HIV-positive drug users and its facilitators 
and barriers [10]. The results showed that active substance use, depression and low 
social support were associated with poor adherence. On the other hand, receiving 
care in structured settings (e.g. directly observed treatment) and drug addiction 
treatment were associated with higher adherence. The results of this review provide 
insight into the influencing factors of HIV-positive drug users’ adherence to HAART. 
There is one major limitation in this review [10], which is the exclusion of relevant 
qualitative studies. The inclusion of relevant qualitative studies can help to gain a 
deeper understanding of underlying issues in relation to HIV-positive drug users’ 
adherence to HAART.  
Taken together, while some research has identified drug users as a less adherent 
group, uncertainty remains as to why this HIV subgroup is less adherent compared 
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to other HIV populations. Therefore, this review aims to critically review international 
quantitative and qualitative literature relating to HIV-positive drug users’ adherence 
to HAART. Through a review of the relevant literature, it can provide a 
comprehensive understanding of HIV-positive drug users’ adherence to HAART and 
its underlying issues, and identify any knowledge gaps and inconsistencies within the 
current evidence base.  
Methods 
Through the process of a literature search, it was revealed that all included 
quantitative studies used a non-experimental design with various adherence 
assessment approaches and standards to investigate drug users’ adherence levels. 
As a result, pooling a meta-analysis or meta-regression of separate studies to 
estimate the overall adherence rate and identify its significant influencing factors 
across studies becomes less meaningful. In an attempt to synthesise the quantitative 
and qualitative studies, an integrated literature review was, therefore, carried out to 
systematically categorise and thematically analyse the selected studies based on 
their characteristics and findings [17]. Meta-ethnography was used to compare 
conceptual data from the included qualitative studies to identify and develop 
overarching themes [18].  
Search strategy 
A search was performed using the databases of the Applied Social Sciences Index 
and Abstract (ASSIA), Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Medline, Embase and PsycINFO (Ovid interface). The keywords used in 
the search were ‘antiretroviral’ OR ‘HAART’ AND ‘adherence’ OR ‘adher*’ OR 
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‘compliance’ OR ‘non-adherence’ OR ’non-compliance’ OR ‘concordance’ AND ‘HIV’ 
OR ‘AIDS’ AND ‘drug use’ OR ‘intravenous drug use’ OR ‘injecting drug use’. 
Inclusion and exclusion criteria 
 
Inclusion criteria: 
1. Studies that involved HIV-positive drug users  
2. Study sample is at the age of 18 or older 
3. Published in English or Traditional Chinese  
4. Empirical studies that focus on adherence to HAART 
5. Qualitative, quantitative, and mixed-methods studies, and dissertations (grey 
literature) 
6. With full text 
7. Studies from 2000 to July 2018 
Exclusion Criteria: 
1. Studies that did not involve HIV-positive drug users 
2. Study sample is less than18 years old                                     
3. Simplified Chinese  
4. Unclear study methodology  
5. Studies that did not focus on adherence to HAART 
 
Articles published in traditional Chinese and dissertations set in the inclusion criteria 
are to maximise the chance of finding empirical studies and to reduce publication 
bias. In terms of the language selection, literature written in English and the first 
author’s original language, traditional Chinese, was included in the search.  
Reporting study selection 
Figure 1 shows the PRISMA diagram for the search that led to the final included 
studies in this review. This literature search included studies from 2000 to July, 2018. 
The literature searched was restricted to dates from 2000 onwards due to combined 
HAART regimens accelerated during the early 2000s, called HAART era, and the 
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overwhelming amount of quantitative literature relating to adherence to HAART. 
Through the search strategy, 3968 articles were generated from the databases. 
Based on the inclusion and exclusion criteria, 3848 articles were excluded during the 
title screening stage, leaving 120 studies. After removal of the articles that did not 
meet the criteria, abstract and full-text screening eliminated further 74 articles. Five 
articles were hand-searched and included, leaving 51 articles for inclusion in this 
review. At abstract and full-text screening stage, numerous quantitative studies in 
relation to HIV-positive drug users’ adherence to HAART were identified as opposed 
to qualitative studies.  The study selection process and the rationale for exclusion 
are shown in Figure 1. Summary of selected studies is presented in Table 1 and 2. 
Results 
Characteristics of the included studies 
Of the retrieved quantitative studies (n=40), 13 were from Canada, 20 from the 
United States of America (USA), 4 from France, 1 from the Netherlands, 1 from India 
and 1 from Vietnam (Table 1). Of the 13 articles from Canada, 11 were from the 
same prospective and ongoing research project in Vancouver. The 4 articles from 
France were also derived from the same prospective research project. In total, 26 
articles were prospective studies (the follow-up period, ranging from 1 month to 91 
months), 12 cross-sectional, and 1 secondary data analysis. There were 27 studies 
involving HIV-positive drug users (either illicit drug users or injecting drug users); 1 
involving methadone maintained patients; 7 studies involving HIV-positive substance 
users with a clear sample description of what constitutes substance users;  5 studies 
involving HIV-positive individuals divided into subgroups (active drug users, past 
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drug users, and non-drug users). All of the included quantitative studies recruited 
sample through convenient and/or snowball sampling.  
The retrieved quantitative studies predominantly focused on levels of adherence, 
and its influencing factors, however, these studies defined adherence in a variety of 
ways and used different measurement tools. Most studies measured participants’ 
levels of adherence to HAART through self-report (continuous variable: doses 
taken/total prescribed doses during certain period of time, or ordinal variable: self-
rating adherence level), pharmacy dispensation record (the number of days patients 
received HAART refills/the total number of days of medical follow-up), or electronic 
monitoring system (Medication Events Monitoring System caps, MEMS caps). Three 
studies focused on drug users’ discontinuation of HAART. Four measured the mean 
adherence rate across study participants. Of the studies measuring drug users’ 
adherence with a continuous scale, 19 studies defined adherence as taking ≥95% 
prescribed doses, 2 defined adherence as taking ≥90% prescribed doses, 4 defined 
adherence as taking 100% prescribed doses, and 2 defined it as taking ≥ 80% 
prescribed doses..  
In terms of qualitative studies, 11 were retrieved for this review (Table 2). There 
were a paucity of qualitative research focusing on HIV-positive drug users’ 
experiences of adherence to HAART at the literature screening stage. All the 
qualitative studies that involved HIV-positive drug users’ experiences of taking 
HAART were included in this review. Although some included studies had not gone 
much further than describing and summarising what participants said, participants’ 
statements presented in the studies still allows readers to see the voice of HIV-
positive drug users regarding their HAART taking. In other words, the quality of these 
qualitative studies was assessed according to the degree to which authors 
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represented the views of their participants [19]. Of the 11 qualitative studies, 2 were 
from Canada, 3 from the USA, 1 from Spain, 2 from Russia, 1 from Ukraine, 1 from 
India, and 1 from the Netherlands. Of the included studies, 4 studies used thematic 
analysis, 2 used framework analysis, 1 used content analysis, 1 conducted 
ethnographic interviews, 2 followed Strauss and Corbin’s codification process [20], 
and 1 followed Glaser and Strauss’s analytic approach [21].   
In the following sections, the quantitative findings related to adherence rates is firstly 
introduced, followed by the synthesis of quantitative and qualitative findings 
pertaining to the factors that influence adherence. 
An estimate of adherence levels among HIV-positive drug users 
Ten studies involving only drug users and defining adherence as taking ≥95% 
prescribed doses revealed that drug users who had ≥95% adherence ranged from 
19.3% to 85.9% [22-31]. However, this result largely represented the USA and 
Canada, because 7 out of the 10 studies were from Canada [23-29], and 3 were 
from the USA [22, 30, 31]. Two studies from France, involving IDUs and using 80% 
as the cut-off point for adherence, showed that 65.2% of 164 IDUs in Moatti’s study 
[32] and 70% of 210 IDUs in Bouhnik’s study [33] had ≥ 80% adherence. One cross-
sectional study by Arnsten et al. [34] measured 636 HIV-positive drug users’ 
adherence rate with use of 90% as the cut-off point for good adherence, showing 
that 75% of them had ≥ 90% adherence. Two studies from the USA, involving HIV-
positive substance abusers (illicit drugs and alcohol abusers) and using 100% as the 
cut-off point, showed that 46% of 1889 substance abusers in Tucker’s cross-
sectional study [35] and 55% of 1138 substance abusers in Mellins’s cohort study 
[36] had 100% adherence. Two prospective studies by Kalichman et al. [37] and Ti et 
al. [38] measured the average adherence rate among 85 and 587 HIV-positive illicit 
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drug users in the USA and Canada respectively, which were reported to be 
approximately 50%. Compared to former drug users and non-drug users, active drug 
users were reported to be significantly associated with poorer adherence to HAART 
[22, 34, 39-46].  
Drawing on the results, there was an indication that HIV-positive drug users had 
lower adherence rates. Nonetheless, a few included studies showed that HIV-
positive drug users had high adherence rates. For example, one prospective study 
from Vietnam showed that 83% out of 100 HIV-positive drug users had perfect or 
very good adherence at some point (self-reported categorical scale) [43]. Another 
study from the USA reported that the mean adherence rates among low-income HIV-
positive substance abusers ranged from 94.46%-97.97% [47]. The results are not 
consistent across the studies, and the aforementioned studies only measured HIV-
positive drug users/substance abusers’ adherence at some points. Thus, it cannot 
represent participants’ overall adherence levels.  
There are four included studies, Mann et al. from Canada [26], Waldrop-Valverde et 
al. [48], Hinkin et al. [42] from the USA and Lambers et al. [49] from the Netherlands, 
investigating the change in adherence levels.  
The study from the Netherlands showed that 25% of 102 drug users became less 
adherent (was defined by the authors as < 95% adherence) at some points during 
the study period [49]. This indicates that adherence to HAART does not always stay 
at the same level. Congruently, three quantitative studies from Canada and India 
investigated HIV-positive IDUs’ discontinuation of HAART [50-52]. These studies 
showed that 33.8% of 545 IDUs in Hadland’s study [50] in Canada, 44% of 160 IDUs 
11 
 
in Kerr’s study [51] in Canada, and 32.7% of 226 IDUs in Sharma’s study [52] in 
India discontinued HAART during the follow-up period.   
In terms of the trend of HIV-positive drug users’ adherence levels over time, the 
prospective study from Mann et al. [26] looked into pharmacy dispensation records, 
and the results showed that the proportion of achieving ≥ 95% adherence among 
HIV-positive drug users increased over time, from 19.3% in 1996 to 65.9% in 2009. 
By contrast, a prospective study from Waldrop-Valverde et al. [48] investigated 
cocaine users’ adherence levels using an electronic monitoring device, and the 
results showed that there was a significant drop in adherence from Month 1 to Month 
6. The reduction in percentage dose adherence was from 76.7% at Month 1 to 
66.5% at Month 6. The difference in the adherence rates over time was found to be 
due to personal factor in Waldrop-Valverde’s study [48] and the advance of HAART 
in Mann’s study [26]. Mann’s study [26] investigated drug users’ adherence levels 
over a longer period of time, from the early era of HAART to more recent era of 
HAART. The advance in HAART has changed the form of HAART regimens, 
contributing to increased adherence rates over that period of time [26]. As opposed 
to Mann’s study [26], the follow-up period was shorter in Waldrop-Valverde’s study 
[48], and the decrease in adherence rates among drug users was reported to be 
more associated with self-efficacy of taking HAART. In a longitudinal study by Hinkin 
et al. [42], it was revealed that both drug positive and drug negative groups had a 
decrease in adherence rates over time. The mean adherence rate had dropped from 
77.4% to 68.4% in the drug negative group, whereas there was a significant 
decrease in the adherence rate among the drug positive group, from 70.1% to 
51.3%. The trend of the adherence rate in the entire sample was from 74.4% for the 
first 2 months, to 68.5% for month 3, and down to 62.6% for month 5 and 6.   
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By and large, the results of the included quantitative studies demonstrated the 
adherence rates among HIV-positive drug users, and its dynamic process. However, 
it is not without limitations. Firstly, as most of the included studies used convenient 
sampling methods to recruit participants, the adherence rates cannot be 
representative of HIV-positive drug users [53]. Secondly, most of the included 
studies used self-report or pharmacy dispensation records to assess adherence 
rates. Self-report measure may bring social desirability bias or recall bias in research 
[54]. Nevertheless, it has been reported that drug users’ self-report was correlated 
with patients’ clinical outcomes, criminal records, and interviews, and it has been 
tested as a reliable method [55]. In terms of measuring adherence by using 
pharmacy dispensation records, issues arise as to whether patients who refill 
medications actually take them. This pharmacy record method has been reported by 
Palepu et al. [56] as unreliable because of the insignificant association between HIV-
positive drug users’ adherence level and HIV-1 RNA suppression. Taking this into 
account, measuring adherence levels with more than one method may enhance the 
accuracy of adherence assessment.  
Factors influencing adherence to HAART 
Having gained insight into HIV-positive drug users’ adherence rates in the current 
evidence base, this section focuses on its influencing factors. A multitude of 
influencing factors have been identified and explored in the included qualitative 
studies (n=11). Of the 11 qualitative studies, 8 involved HIV-positive individuals who 
had a history of injecting drugs [57-63]. One involved HIV-positive active drug users 
(smoked/ injecting drug use) [64]. One involved IDUs who use methadone 
maintenance [65]. One involved HIV-positive individuals who had a history of using 
drugs and treatment interruption for 30 days [66].  The conceptual data from the 
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included qualitative studies were compared and contrasted, and were subsequently 
collated into themes, and then the themes was triangulated with relevant quantitative 
evidence in an attempt to gain a comprehensive account of HIV-positive drug users’ 
experiences of taking HAART.  
Throughout the process of comparing findings across the included studies, six 
themes were identified—  
1) Stigmatisation in relation to HIV and illicit drug use 
2) The motivation for taking HAART 
3) Active drug use and HAART adherence 
4) Accessibility and conditionality of HIV and addiction treatment 
5) Side effects and complexity of HAART regimens 
6) Forgetting and not fitting HAART regimen into schedule.  
The six themes are discussed in the following sections. 
Stigmatisation in relation to HIV and illicit drug use 
Stigma was identified as one of the predominant themes. Seven studies reported 
that HIV-positive drug users/inmates had experienced stigmatisation and 
discrimination associated with HIV and illicit drug use [57,59,61-62,64-66]. Some 
experienced violence in the prison settings [62] and others were shunned and 
discriminated by family [57,64-66], police officers [59] and health professionals 
[61,65,67] due to their HIV status. In addition to HIV status, participants’ engagement 
in the everyday violence associated with their drug dependence appeared to 
exacerbate their negative image portrayed by society [66]. 
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Two major factors that led to families’ and public stigmatisation and discrimination 
towards HIV-positive drug users emerged from participants’ statements across the 
included qualitative studies — lack of knowledge relating to HIV, and images of ‘HIV 
and illicit drug use’ discredited by society. As with lack of knowledge, misconceptions 
about the transmission routes of HIV were revealed to bring public fear and lead to 
estrangement. For example, HIV-positive drug-using participants in Mimiaga’s study 
[59] reported that police officers in Ukraine were afraid of them, and avoided physical 
contact from them or even things they had touched. As a result, their experiences of 
stigmatisation had influenced their willingness to access care.  
Three qualitative studies from Ukraine (n=16), India (n=19), and Russia (n=42) 
revealed that health professionals held assumptions in relation to HIV-positive drug 
users’ poor adherence and refused to treat them [57,59,61,67]. Aside from health 
professionals’ negative assumptions of drug users, Pach et al.’s [60] (n=34) and 
Kiriazova et al.’s [67] qualitative studies (n=25) indicated that some drug users did 
not trust health professionals, either. This created the barrier to accessing HIV care.  
With a lack of engagement and trust in the health system, some drug users did not 
have adequate knowledge about HIV and HAART [57,60,64]. As a result, they were 
more likely to gain knowledge of HAART based on information circulating through 
social networks, and held negative assumptions and misinterpretation of HAART 
[57,60,64]. Congruently, Kelly’s study [68] with the use of secondary data analysis 
(n=76) pointed out that having HIV-positive drug users in friend circles was 
associated with less adherence to HAART.  
Experiences of stigmatisation from families has also been reported in Chakrapani’s 
qualitative study [57] in India, where being HIV positive and using illicit drugs were 
perceived by IDUs’ families to bring shame to the whole family. By holding negative 
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perceptions of HIV and illicit drugs, some were forced by their families to move out of 
their house, leading to homelessness [57]. As a consequence, financial instabilities 
(e.g. lack of money, food and housing), social stigmatisation, and disruptions in drug 
users’ daily lives had affected their ability to follow treatment regimens [60,63,64,66]. 
Several quantitative studies also showed the significant association between 
homelessness and nonadherence [23,29,33,39,49]. 
The impact of stigmas related to HIV and illicit drug use not only impeded HIV-
positive drug users’ acquisition of support, but worsened their psychological distress, 
self-stigmatisation, and willingness to seek support [59,63,65,66]. With the feelings 
of denial, shame, and fear of stigmatisation, some tended to not disclose their HIV 
status, and were more likely to hide or not bring HAART medications with them 
[59,64,65]. In some cases, HIV-positive drug users articulated their low levels of 
motivation to live and take HAART [59,63,66].  
In line with the findings derived from the qualitative studies, the included quantitative 
studies indicated that HIV-positive drug users’ poor adherence to HAART was 
significantly associated with their psychological distress or depression 
[34,36,39,45,69]. In addition, two studies from the USA by Magidson et al. [47] and 
France by Moatti et al. [32] indicated that environmental punishment (perception of 
being exposed to punishing experience) and frequency of negative life events were 
related to poor adherence to HAART. Of particular concern, environmental 
punishment was the mediator between depression and poor adherence [47]. The 
results illustrated the influence of social environment on individuals’ psychological 
well-being and subsequent HAART-taking behaviour.  
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In brief, it seemed that stigma related to HIV and illicit drug use could pose an impact 
on HIV-positive drug users’ acquisition of support. Without the support available for 
them, it can further increase drug users’ levels of perceived stigma and 
psychological distress. Social and self-stigmatisation was revealed to be linked to the 
lack of knowledge pertaining to HIV and illicit drug users, and the influence of social 
values.  
Motivation for taking HAART  
Despite the impact of stigma on HIV-positive drug users’ HAART-taking behaviour, 
some HIV-positive drug users appeared to be motivated to take HAART. Two factors 
were identified to enhance HIV-positive drug users’ motivation of taking HAART— 
acceptance of HIV status and acquisition of support from health professionals, family 
or friends [58,-60,63-65]. With the acquisition of support, it facilitated affected 
individuals’ life stability and adherence to HAART by providing tangible support 
[59,60,64]. In addition, drug users having a stable job has been identified as a factor 
enhancing their sense of responsibility and level of motivation to adhere to HAART 
[64,70].  
One qualitative study (n=23) by de la Hera et al. [58] pointed out that maintaining a 
good relationship between health professional and HIV-positive drug users 
enhanced drug users’ knowledge related to HAART management. In turn, drug users 
with adequate knowledge were found to be more likely to be aware of their HAART-
taking acts and managed HAART more consciously. Aside from external support, 
internally, drug users’ self-acceptance and wanting to live longer were revealed to 
strengthen their will to adhere to HAART [59,64,65]. 
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Drawing on the qualitative findings from the included studies, HIV-positive drug 
users’ motivation to take HAART seemed to be influenced by the degree of support 
they got and their self-acceptance. As such, it had helped drug users grow belief and 
confidence in their capacity for taking HAART [58,65].    
Active drug use and HAART adherence 
The majority of the included quantitative studies indicated that illicit drug use 
significantly and negatively affected HIV-positive drug users’ adherence to HAART 
[9,22-24, 33,36,39,41-43,45,47,52,69,71-73]. A longitudinal study conducted in New 
York by French et al. [22] investigated the impact of the change in substance abuse 
on participants’ adherence to HAART. The result showed that participants who 
changed from no substance use at one interview to substance use at the follow-up 
interview were more likely to transition from adherence to non-adherence. However, 
this paper does not specify the patterns of drug use among the participants. It would 
enhance understanding if this study had included more details about the dynamics of 
drug use as to whether participants experienced relapse or just started using illicit 
drugs. The tendency to use drugs to cope with stress was reported in Arnsten’s 
prospective study [39] to be significantly associated with non-adherence to HAART. 
This indicates that drugs could be used as a coping strategy by users to deal with 
stress, resulting in poor adherence.  
Concerned about the impact of drug use on adherence, getting a fix was the heroin 
users’ main focus [57-60,63,64]. The large amount of time active drug users spent 
on pursuing their next fix had affected their ability to access health care [59,60]. In 
addition, the large sum of money spent on heroin placed HIV-positive drug users in 
poor financial circumstances [63,64]. Drawing on the findings, both stigma and illicit 
drug use were revealed to collectively increase HIV-positive drug users’ vulnerability 
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related to incarceration, employment, family relationships, mental health, and access 
to care, contributing to breakdowns in the continuity of HIV care [24,49,51,64,66].  
Congruent with the qualitative research findings, Mellins et al. [36] and Tucker et al. 
[35] in their cross-sectional studies reported that HIV-positive drug users’ non-
adherence to HAART was associated with low attendance rates at a medical 
appointment and poor integration of the medication regimens into their lifestyle. 
Wittveen and Ameijden [63] in their ethnographic interviews noticed that the drug use 
patterns among drug-taking adherers ranged from using drugs once a day to using 
drugs once a month. Although Wittveen and Ameijden [63] did not further explain 
what enabled them to regularly use illicit drugs and take HAART medications, they 
pointed out that methadone had alleviated participants’ withdrawal symptoms and 
stabilised their emotions, further enhancing their adherence to HAART. In line with 
this, numerous included quantitative studies also reported methadone maintenance 
treatment was significantly related to adherence to HAART among HIV-positive drug 
users [24,25,27,29,31,41,49,71,72,74]. These findings are incongruent with the 
results of a cross-sectional study with 133 methadone users by Shrestha and 
Copenhaver [75] which indicated that methadone users who continue using drugs 
were more likely to have suboptimal adherence and incomplete viral suppression. 
In summary, it seemed that the addictive effects of illicit drugs could disrupt HIV-
positive drug users’ lifestyle and their ability to access HIV care, whereas methadone 
appeared to have the protective effect of alleviating their withdrawal symptoms and 
enhancing adherence. However, due to the prevalence of methadone users who 
continue injecting drugs [75], the impact of methadone use on affected individuals’ 
drug-taking and adherence behaviour remains complex, which requires future 
research on their complex interplay.  
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Accessibility and conditionality of HIV and addiction treatment 
Though HAART and addiction treatments play an important role in facilitating HIV-
positive individuals’ adherence to HAART, some drug users articulated the difficulty 
in accessing HIV and addiction care [52,57,60-62,66,67]. The accessibility of HIV 
and addiction care varied from country to country. Sharma’s cross-sectional study 
[52] from India illustrated that the financial cost of HIV diagnostic testing, treatment of 
opportunistic infections, and transport significantly increased HIV-positive drug users’ 
financial burden and impeded their access to HAART. In correctional systems, 
issues in relation to difficulty accessing HIV medications were reported in two 
qualitative studies by McNeil et al. [66] and Small et al. [62] in Canada. In the two 
studies, some participants complained about the unavailability of HIV medication 
between the times of arrest, trial, and arrival at the institution where they served their 
sentence, and upon release from custody [62,66]. As such, these structural factors 
increased the challenge of drug users’ access to HIV care.    
In addition to these structural factors, two qualitative studies from Russian and India 
revealed that HIV treatment conditionality was a great hindrance of access to HIV 
care among HIV-positive drug users [57,61]. In Chakrapani’s [57] and Rhodes and 
Sarang’s [61] studies, physicians’ provision of HAART to HIV-positive drug users 
appeared to be contingent. Physicians provided HAART to affected individuals, only 
when affected individuals could show evidence that they were reliable, deserved 
taking HAART, and were able to be in control of their drug use. Such value 
judgement was upheld by physicians’ concerns in an attempt to decrease drug 
resistance, maximise treatment outcomes, and adapt to economic constraints within 
healthcare [57,61]. As a result, it had led to delayed access to care, treatment 
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interruption, or disengagement from health care among HIV-positive drug users 
[57,61].  
Such ways of treating HIV-positive drug users situated HAART as a relative priority 
in the hierarchy of immediate need where managing the ‘problems’ of illicit drug use 
came first. Moreover, this policy was revealed to be put in place due to physicians’ 
doubts of drug users’ capacity to adhere to HAART in the face of ongoing and 
untreated drug use [57,61]. In addition to the conditionality of access to HIV care, 
HIV-positive drug users’ accounts, in the qualitative studies by Pach et al. [60] from 
the US (n=34 HIV+ IDUs), Chakrapani et al. [57] from India (n=19 HIV+ IDUs), and 
Rhodes and Sarang [61] from Russia (n=42 HIV+ IDUs), showed the inadequacy 
and ineffectiveness of addiction treatment, and a lack of effective linkage between 
HIV care and drug dependence treatment/needle syringe programme. In contrast to 
the findings from these studies, easy access to HAART was reported by HIV-positive 
drug users who had a good relationship with health professionals in a qualitative 
study by de la Hera et al. [58] from Spain (n=23 HIV+ IDUs). Drawing on the findings 
from the aforementioned studies, it seemed that the accessibility of HIV care can 
also be linked to the establishment of the trusting relationship between health 
professionals and HIV-positive drug users.   
Although infrastructure within healthcare varies from country to country, the findings 
from the included studies pointed out that it still created a barrier to individuals’ 
willingness to access care, especially for those who were in a financially 
disadvantaged situation. In addition, the distrusting relationship between healthcare 
providers and HIV-positive drug users could also widen the accessibility gap.  
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Side effects and complexity of HAART regimens 
Side effects have been reported by several qualitative studies and one cross-
sectional study as a barrier to adherence to HAART among HIV-positive drug users 
[52,59,60,63,67]. The commonly reported side effects were diarrhoea, fatigue, 
nausea, vomiting, and stomach-aches [52,59,60,63,67]. Some had treatment 
interruption due to the experience of side effects [52,59,60,63,67], and others did not 
receive HAART because of their misconception and concerns over the toxicity and 
danger of taking the treatment [60,66]. 
For HIV-positive drug users who started HAART in the early to mid-1990s or lived in 
a country where HAART options were limited (such as Ukraine), complexity of the 
treatment regimen was reported to influence their adherence to HAART [58-
59,63,66]. A qualitative study by Mimiaga et al. [59] from Ukraine pointed out that 
several participants found it challenging to adhere to HAART due to high pill counts, 
the necessity of taking medications at specific times, and with food restrictions. 
Nonetheless, McNeil’s study [66] from Canada indicated that the use of modern 
HAART has transformed the treatment regimens into a more simplified form, which 
had enhanced participants’ adherence.  
To sum up, the advance in HAART regimen globally has simplified the way that 
individuals take HAART regimens, and has decreased individuals’ burden of taking 
HAART. Nonetheless, ‘side effects’ of HAART remained one of the major barriers to 
adherence to HAART in the included studies. Misconception and experience of side 
effects of HAART were found to exert an impact on receiving and/or continuing 
HAART among participants in the included studies. 
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Forgetting and not fitting HAART regimen into schedule 
Fitting HAART regimen into daily schedules has been reported to bring challenges to 
adherence to HAART among drug users [59,63,76]. Though this theme emerged in 
the included qualitative studies, there was a lack of explanation and exploration in 
the studies as to in what situations or how HIV-positive drug users were more likely 
to forget doses and not incorporate HAART into life.  
To avoid forgetfulness, some HIV-positive drug users, from Wittveen and Ameijden’s 
[63], Mimiaga’s [59], Ware’s [64] qualitative studies, developed strategies to 
promoting adherence to treatment. The strategies included incorporating medication 
regimens into drug use routines, use of medication containers, phone alarms/alarm 
clocks, or stickers to remind their dosing schedules. Some took HIV medications with 
them all the time [59,63].   
Discussion 
Drawing on the quantitative results from the included studies, the proportion of HIV-
positive drug users who achieved ≥ 95% adherence across the studies varies widely 
across and within countries, from 19.3%-83.9% [22-31]. This indicates that 
adherence rates tended to be inconsistent amongst the included studies. Drug users’ 
adherence levels could drop and change over time [42,48,50-52]. Over the course of 
receiving HAART, many drug users had a history of discontinuing HAART at some 
points [50-52]. The average adherence rate was approximately 50% [37-38]. 
However, the advance in HAART, from complex regimens to simplified regimens, 
have enhanced the level of adherence among HIV-positive drug users [26]. This 
indicates that HIV-positive drug users’ HAART-taking behaviour is an ongoing and 
dynamic social process where the patterns of their HAART-taking behaviour did not 
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remain the same but fluctuated over time. Although several attempts have been 
made to assess HIV-positive individuals’ adherence levels by using self-reported 
questionnaires, pharmacy dispensing records or electronic monitoring devices, 
current assessment tools cannot capture the dynamic process of drug users’ 
HAART-taking behaviour. In that sense, the question with regards whether HIV-
positive drug users adhere to HAART cannot be simply answered as one or the 
other. Therefore, the review of qualitative studies played an important role in this 
paper to deeply understand and explore drug users’ experiences of taking HAART 
Among HIV-positive drug users, active drug use was reported to be significantly 
associated with poor adherence to HAART [22,34,39-46]. In particular, the impact of 
drug use on drug users’ lifestyle and financial instability was found to be linked to 
their poor adherence to HAART [57-60,63,64]. Furthering the results from 
quantitative studies, the included qualitative studies showed that active drug use, 
specifically heroin, was found to affect participants’ decision of prioritising needs. 
They tended to prioritise the need of getting fixed over enhancing health condition, 
resulting in decreasing their motivation of taking HAART. In response to stress, drug 
use was reported in Arnsten et al. [39] prospective study as a coping strategy among 
HIV-positive drug users. These findings imply the complex relationships between 
individuals’ emotion, coping, and HAART-taking behaviour. As a result, active drug 
use had increased the challenge of initiating and sustaining HAART use among HIV-
positive drug users. On the other hand, methadone treatment was reported to have a 
protective effect on enhancing adherence [24,25,27,29,31,41,63,71,72,74].  
In addition to drug use, stigma related to HIV and illicit drug use was revealed in the 
included studies to greatly impede drug users’ access to care and adherence to 
HAART [57,59,61,62,64,65]. In particular, the included qualitative studies from the 
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middle/low-income countries tended to report the negative impact of social stigma on 
HIV-positive drug users’ adherence to HAART compared to those from high income 
countries. Public lack of knowledge and social values attached to HIV and drug use 
were found to shape one’s assumptions and stigmatisation towards HIV-positive 
drug users. Drug users’ experiences of stigmatisation from family, health 
professionals, and friends could undermine their psychological wellbeing and delay 
their access to HIV treatment. Participants’ experiences of stigmatisation was shown 
to affect their psychological well-being, self-stigmatisation, and willingness to seek 
support and regularly receive HAART. By contrast, self-acceptance and acquisition 
of support were identified to enhance HIV-positive drug users’ motivation of taking 
HAART.  
Infrastructures within healthcare were another factor revealed in the included studies 
to impede participants’ access to HIV and addiction treatment. Accessibility of care 
was particularly found, in the qualitative studies from Russia and India, to be linked 
to the economic constraints and value judgement towards drug users within the 
society [57,61]. As for HAART regimens, concerns over side effects were revealed to 
shape participants’ preconception of HAART and decrease their willingness to take 
HAART. Not fitting HAART regimen into everyday life was reported to increase the 
chance of missing doses. 
Together, based on the results from the included studies, there are several 
implications for practice, policy and future research. In practice, firstly, it is 
recommended that health professionals should assess HIV-positive drug users’ 
adherence to HAART on a regular basis, given the dynamic and fluid process of drug 
users’ adherence to HAART. Secondly, this paper recommends health professionals 
to provide care to HIV-positive drug users with respect, dignity, and non-judgemental 
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attitudes. Thirdly, it is suggested that HIV-positive drug users’ psychological well-
being, support system, and experience of HAART taking should be incorporated and 
emphasised in the care plan. The provision of coping strategies by health 
professionals and peer support groups, with regards the common issues 
experienced by drug users, can enable them to manage HAART taking more 
effectively. Fourthly, this review stresses the importance of linking HIV care with 
addiction care and prison settings. In doing so, it can help to retain HIV-positive drug 
users’ access to HIV care and optimise their health outcomes.  
For policy uptake, this review offers suggestive evidence for policy makers to create 
a supporting and inclusive environment for HIV-positive drug users to minimise 
social stigmatisation. Policy makers can take the initiative to increase the 
accessibility of HIV care in communities and prison settings, and bridge the gaps 
between HIV and addiction services. In addition, this paper suggests that national 
governments should ensure the rights of HIV-positive drug users are protected, 
thereby they can access health and social services without fear of discrimination or 
stigmatisation.  
In terms of implications for future research, although quantitative research on HIV-
positive drug users’ adherence rates has been conducted extensively, there is a 
paucity of qualitative research focusing on HIV-positive drug users’ experiences of 
HAART taking. This review suggests the need to gain insight into their experiences 
of taking HAART and further develop a model or framework that can enhance 
understanding their adherence behaviour. This can provide a guideline for policy 
makers and health professionals to assess HIV-positive drug users’ adherence to 
HIV care, and further develop associated interventions. 
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While this review provides a comprehensive understanding of HIV-positive drug 
users’ adherence rates across the studies and the influencing factors, there are 
limitations. Firstly, this review article did not conduct statistical tests. Due to different 
standards of optimal adherence rates and adherence assessment tools used by the 
included studies, this increased the difficulties of estimating HIV-positive drug users’ 
adherence levels. Secondly, during the process of this systematic literature review, 
expert discussion panels were not involved in the reviewing process. Consequently, 
this may bring authors’ biases into the analysis. Last but not least, all of the included 
studies assess HIV-positive drug users’ adherence levels and experience of HAART 
taking through self-report. This might lead to overestimation of their adherence levels 
and introduction of socially-desirable answers when synthesising the evidence.  
Conclusion 
This is the first review article that includes both qualitative and quantitative research, 
and provides a more comprehensive and in-depth understanding of HIV-positive 
drug users’ experience of HAART-taking.  The results from this review can provide 
insight into the underlying issues that could potentially influence HIV-positive drug 
users’ adherence to HAART. However, the mechanism of HAART-taking behaviour 
in HIV-positive drug users remains to be elucidated. This would be fruitful area for 
further work to ensure appropriate system, services, and support for this group of the 
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CINAHL (N=1074)           
ASSIA (N=756)                   
Ovid database (Medline, 
Embase, and PsycINFO) 
(N=2137)                         
Thesis: 
CINAHL (N=0)                
ASSIA (N=0)                       
Ovid (N=1)                                 
         
 
Reasons for excluding the articles 
during the title screening stage 
(N=3848):                                          
1. Intervention research                     
2. Children.                                        
3. Sample is not HIV-positive drug 
users                                                 
4. Not related to antiretroviral 
adherence or non-adherence                         
5. Duplicates 









Remaining articles for 
the abstract and full 







Reasons for excluding the articles 
(N=74):                                               
1. Small sample size of drug users 
group                                                   
2. Full text is not accessible                                   
3. Examining the effectiveness of 
interventions                                                                
4. Aims were to test adherence 
measurement                                      
5. Review literature                            
6. Did not define adherence or 
explain how 95% adherence was 
measured                                      
7. Unclear definition of substance 
abusers                                              
8. Not focusing on drug users, and 
simply reporting the association 
between adherence and drug use 
among general HIV population                                       
9. Results drawing from an 
intervention evaluation research,. 
Simply reporting the association 
between appearance concerns and 
non-adherence.                                         
10. Focusing on viral suppression 
or CD4 count not adherence                 
11. Dependent variable is 
acceptance of HAART or health 
seeking behaviour                        
12. Not drug users but persons 
with incarceration or sexual abuse  
13. Simply reporting the 
association between adherence 
and influencing factors without 
explicit explanation                      
Articles were 
assessed for eligibility 
(N=46) 
11 qualitative studies, 40 
quantitative studies were 












Hand searched 3 articles 
from the reference lists of 
systematic review articles     
Two recently-published 
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period 










Azar et al. 
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2013) 
























The ratio of 


















51% of the 
participants were 
categorised by 
≥95% adherence.  
 
 


























Adherence is a 
mediator of the 
relationship 









There were 26.6% 
periods in which 
individuals were 
more than 95% 
adherent in 4460 
observations 






refill adherence for 
antiretroviral 
medications and 


























some point during 
the study period.  
Older age and 
higher CD4 count 
were associated 
with optimal 
adherence.   
Daily Cocaine and 
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people who use 
illicit opioids 


























Transition out of 
optimal adherence 












Periods of sex 
work and injecting 








and had a 
protective effect 
against being non-
adherent.   
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The proportion of 
achieving at least 
95% adherence 
increased over 
time from 19.3% 
in 1996 to 65.9% 
in 2009.  
Initiation year was 
associated with ≥ 
95% adherence.  
Nolan et al. (2011) 
/(1996-2008) 
Title: Adherence 
and plasma HIV 
















30% of the 267 
participants had ≥ 
95% of adherence 
during the first 
year of ART. 
≥95% adherence, 
participation in 
MMT, and older 















drug users: The 
role of methadone 
maintenance 
therapy 







129 out of 278 
had ≥ 95% 
adherence 
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Drugs 





85.9% of 650 
participants 
achieved 95% or 
greater ART 
adherence at 
some point during 











in MMT, and CD4 
cell count, while 

















workers who use 






















between sex work 
and suppression 
of viral load 
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was defined as 





359 were IDUs 
(25.3%).  
History of injection 





At 12 months of 
after ART 
initiation, 30.3% of 
non-IDU versus 
42.5% of IDU had 
discontinued 












and adherence to, 
antiretroviral 




refers to the 
sustained use of 
ART, and is the 
opposite of 
In total, 71 (44%) 
participants 
discontinued 





Published article therapy among 
injection drug 
users living with 
HIV/AIDS 








which refers to 




They had not 
picked up any 
components of 
their HAART 

































study in New 
York 
French et al. 
(2011) 
 





with Changes in 








(use of cocaine, 
crack, heroin in 




number of pills 
prescribed per 
day and the 
number of doses 
they missed in 
the 3 days  
71.7% of 2089 
had ≤ 95% 
adherence 
Clients who 
changed from no 
substance use at 
one interview to 












being not sure to 
very sure about 
the effectiveness 
of ART were 
significantly more 




changed from low 
stress to high 
stress were three 
times more likely 





study in 9 states 
of the USA 
Chitsaz et al. 
(2013) 
Title: Contribution 
of substance use 














number of pills 
prescribed per 
day and the 
number of doses 
they missed in 
the 7 days  
 
Among all 
subjects, 72% had 
used drugs in the 
30 days. 
Drug use severity 
was negatively 
correlated with 1) 
having an HIV 
care provider, 2) 
being prescribed 




and paid for work 
was associated 













study in multiple 
sites of USA 
Sharpe et al. 
(2004) 
Title: Crack 













measured with a 
single question, 
“How often are 
you able to take 
the HIV/AIDS 
drugs exactly the 
way your doctor 








always and not 
always. 
Crack users and 
users of other 
drugs were less 
likely than non-





study in South 
Florida  







abusers: the role 
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One in five was 






are stabilised on 
methadone 
remain at high risk 





























percent of doses 
taken during the 
previous 7 days. 
4-week interval for 
follow-up, over 6 
month period 
Compared to the 
first month, there 
was a significant 
drop in adherence 
at Months 2, 3, 4, 
and 6 for 
percentage dose 
adherent. 
There was a 
reduction from 
76.7 at Month 1 to 




66.4 at M1 to 57.3 












with adherence to 
antiretroviral 















doses to never 
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Hicks et al. (2007) 
Title: The impact 
of illicit drug use 
and substance 
abuse treatment 










doses missed in 
the past 2 weeks. 
Adherence was 
defined as taking 
greater than or 




drugs in the 
HAART regimen 





likely to be 
adherent than 
former (68%) or 
never users (77%) 
Former users in 
substance abuse 
treatment were as 
adherent to 
HAART as never 
users 
Former users who 









































































of doses taken 
during the 





The majority of 
participants were 
MSM (94%). 
Among the MSM, 
84% identified as 
predominantly or 
exclusively gay. 
Positive affect was 
independently 




injection drug use 











adherence to ART 
A multisite 
cohort study 





medical care in 
HIV-infected 
adults diagnosed 
with mental and 









missed doses in 
the past three 
days 
Complete 
adherence in the 
past 3 days: 55% 
of the participants 
45% of those on 
ARVs reported 
skipping 
medications in the 




















































number of doses 
missed versus 
doses prescribed 
over the past 4 
days for all daily 
medications 
Mean adherence 
rates ranged from 
94.46 to 97.72 % 
in the past 4 days 




There was only an 
































































users (use within 

























and Mental Health 
Problems 
N=1889  HIV-positive 
individuals (23% 








46% of the 
participants were 
adherent 
Those in the drug 
use only group 
were not 
significantly more 
likely to be 
nonadherent than 
those with no 




group was more 
likely than those 
with no problems 
to have poor 
access. 
Drug use group 
was more likely to 
report poorer fit of 
the medication 









With HIV Infection: 




























the past 7 days at 
three-time points, 
baseline, Week 
12, and Week 24. 
Adherence was 
dichotomized as 
either 100% (no 
missed doses or 
pills any time in 








drug use on the 










report of more 
than two missed 
doses over the 2 
weeks 
Active drug users 




of active drug 
users failed to 
utilise HAART 
compared with 
22% of former 
drug users and 




Hinkin et al. 
(2007) 












dose events by 
prescribed doses 
during 1 month 
period 
Adherence: 




rate was 79% as 





for the entire 
sample dropped 
from 74.4% for the 
first 2 months, to 
68.5% for months 
48 
 
3–4, down to 
62.6% for months 






than both the 
other-drug positive 
group (P = .001) 










than did the 
cocaine only 
group. The mean 
adherence rate for 
the cocaine only 
group was 68.1% 




Drug use was 
associated with 
4.1 times greater 
risk of being a 







10% points, from 
77.4% to 68.4%, 
the drug abuse 
group experienced 
a more precipitous 
decline with their 
mean adherence 
rate dropping over 
18% points (from 
70.1% to 51.3%). 
Cross-sectional 
study 






























Arnsten et al. 
(2002) 
Title: Impact of 





in HIV infected 
drug users 
N=85 HIV-positive 







the number of 
cap opening  by 








use, female, not 
receiving social 
security benefits, 
not being married, 
positive for 
depression, the 
tendency to use 
alcohol or drugs to 







predictor of poor 
adherence was 
active drug use. 
Adherence among 
active cocaine 
users was 20%, 
compared to 66% 
in subjects who 













Active Drug Users 










indicated that they 
intentionally miss 
their ART when 




of mixing HIV 
medications with 

















Turner et al. 
(2003) 
N=1827 (female) 
N= 3246 (male) 






















22% of the study 
population were 















for those with 












Carrieri et al. 
(2003) 
Title: Failure to 
Maintain 
Adherence to 
HAART in a 






N=96 HIV-positive IDUs Convenient 
sampling 
Adherence failure 
is defined as a 
self-reported, 
non-adherence 
behaviour at any 
visit before the 








during the week 
prior to the visit.  
Non-adherence 
means taking 








adherent at all 
follow-up visits. 
Lack of a stable 
relationship, active 






Moatti et al. 
(2000) 
Title: Adherence 
to HAART in 
French HIV-
infected injecting 










less than <80% 
of prescribed 
doses in the past 
7 days 
34.8% took less 












events during the 
prior 6 months 










drug users: The 
impact of social 
instability  
N=210 HIV-positive 























Roux et al. (2008) 
Title: The impact 








evidence from the 
MANIF2000 
cohort study 






was used to 
reclassify as non-
adherent those 




HAART in the 4 
days and in the 4 










injection, on OST 



































number of days 
that medication 
was not taken in 
the last 6 
months. 
The rate of non-
adherence (95%)  
ranged from a 
minimum rate of 
6.2% (in 2002) to 
a maximum rate of 
18.9% (in 2005) of 
the visits per year. 
Of the 76 
participants who 
were adherent on 
their first included 
visit and who had 
a follow-up visit, 
26 became non-
adherent at least 














at home) and 
















Jordan et al. 
(2014) 
Title: Correlates of 
non-adherence to 
antiretroviral 





therapy in Hanoi, 
Vietnam 
N=100 HIV-positive 
individuals with a 










reported drug use 
within the previous 
6 months, with 
22% reporting 
current drug use.  
 
Overall levels of 
self-reported ART 
adherence in this 
cohort were high 
(83% reporting 
perfect/very good 
adherence at the 
time of study 
enrollment) 
 
Active drug use 
and duration of 















and impact of 
ARV provision to 
current and ex-
injecting drug 
users in Manipur 
(India): An initial 
assessment 















Experience of side 
effects, whether 









Table 2: Summary of the included qualitative studies (N=11)  
 















maintained drug users  
15 HIV-positive 










Negative themes are related 
to continued drug use 
1. Denial and resistance 
2. Shame 
3. Perceived isolation 
Positive themes are related 
to decreased drug use 
1. Acceptance of HIV and 
motivation to adhere 
2. Empowerment  
3. Perceived connectedness 













- Group 1 (N=8): Never on 
ART 
1. Involving in active drug use 
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among injection drug 
users 
2.Lacking information from 
health professionals about 
HAART 
3. Having ambivalent or 
negative attitudes about the 
safety of the medication and 
the intentions of health care 
providers 
Group2 (N=7): Stopped AZT 
and never sought other 
treatment. 
 1. Active drug use 
2. Lack of contact with HIV 
services 
3. Negative experience with 
side effects from AZT  
4. Exposure to negative 
attitudes about AZT deterred 
members of this group from 
continuing their use of ART or 
later considering the use of 
ART 
Group 3 (N=9): Stopped 
undergoing HAART 
1. Perceptions of HAART that 
altered in significance as their 
circumstances and 
experiences with the 
medication changed (e.g. level 
of drug use, lack of available 
drug treatment, severity of 
side effects, prior experience 
with clinicians) 
Group 4 (N=10): Undergoing 
HAART 
Working, living with relatives, 
receiving disability payments, 
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improved health, trusted 
medical doctors, taking 
HAART in their own ways   
Ware et al. 
(2005) 
Adherence, stereotyping 
and unequal HIV 
treatment for active 
users of illegal drugs 
52 HIV-positive 











1. Daily lives of participants 
2. How drug use impedes 
adherence 
 *Acquiring drugs 
 * Consuming drugs 
 *Recovering from drug use 
3. Not carrying medication 
4.Competing priorities 
5. Redefining regimens 
6. Efforts to adhere to HAART 
  *Taking medications while 
using  
  *Prioritising adherence  
  * Sticking with a set of rules: 
the significance of routines 
for adherence 
Canada Small et al. 
(2009) 
The impact of 
incarceration upon 
adherence to HIV 
treatment among HIV 
positive injection drug 












1. Entry into the correctional 
system and interruption of 
treatment 
2. Difficulties accessing HIV 
medications within the 
correctional system 
3. Challenges related to 
institutional health care 
services and HIV care 
4. The importance of 
advocacy and communication 
5. HIV discrimination amongst 
prisoners 









McNeil et al. 
(2017) 
Antiretroviral therapy 
interruption among HIV 
positive people who use 





drug users who 
had not filled an 
ART prescription 
for a period of at 













1.Individual and contextual 
influences on treatment 
fatigue 
2. Negotiating prior adverse 
ART experiences 
3. Social isolation and 
treatment motivation 
Socio-structural  
1. Structural vulnerability and 
discontinuities in the continuity 
of HIV care 
Russian Rhodes and 
Sarang 
(2012) 
Drug treatment and the 
conditionality of HIV 
treatment access: a 















1. HIV treatment conditionality 
and delay 
2. The problem of drugs in HIV 
treatment access 
3. The problem of inadequate 
drug treatment  
 
 Kiriazova et 
al. (2016) 
“It is easier for me to 
shoot up”: stigma, 
abandonment, and why 
HIV-positive drug users 










1.Stigma and poor patient-
provider relationships 
2. Fragmentation of health 
care 
Ukraine Mimiaga et 
al. (2010) 
“We fear the police, and 
the police fear us”: 
structural and individual 
barriers and facilitators 
to HIV medication 
adherence among 
injection drug users in 
Kiev, Ukraine 










1. Harassment and 
discrimination by police 
2. Opioid dependence  
3. Complexity of drug regimen 
4. Side effects 
5. forgetting 
6. Co-occurring mental health 
problems 









1. Cues for pill taking  
2. Support and reminders from 
family, significant other, and 
friends 
3. Opioid substitution therapy 
4. Wanting improved health 
5. Knowledge about HAART 
6. Storage of medications 
7. IDUs and sexual risk 
behaviours  
India Chakrapani 
et al. (2014) 
Barriers to antiretroviral 
treatment access for 
injecting drug users 
living with HIV in 
Chennai, South India 
19 HIV-positive 
IDUs 










Family and social barriers 
1.Lack family support and fear 
of societal discrimination 
2.Unmet basic needs -  food 
and shelter 
Health care system barriers 
1.Actual or perceived 
unfriendly hospital 
environment and procedures 
2. Provider-perceived 
nonadherence 
3. Actual or perceived 
inadequate counselling 
services and lack of 
confidentiality 
4. Lack of effective linkages 
between ART centres, 
needle/syringe programs, and 
drug dependence treatment 
centres 
Individual-level barriers 
1. Active drug use 











Spain De la Hera et 
al. (2011) 
The opinions of injecting 
drug user HIV patients 
and health professionals 
on access to 
antiretroviral treatment 





















1.Lack of coordination among 
hospital services 
2. Difficulties in accessing 
non-specialised services  
3. Their perceptions of a 
patient’s likelihood of 
treatment adherence 
IDUs 
1. A good doctor-patient 
relationship 
2. Family responsibility 
(Female participants) 
3. Complexity and side effects 
of the treatment 
4. lack of social support 
5. active use of recreational 
drugs 
6. Accessibility of services 
7. Beliefs about HAART 
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